Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma

Radhika Bansal • 5 Jun 2022
ASCO 2022
Multiple Myeloma

Radhika Bansal, MBBS, Mayo Clinic, Rochester, MN, discussses the results of a retrospective study evaluating the use of bone marrow assessment of minimal residual disease (MRD) as a surrogate endpoint in patients with multiple myeloma receiving CAR T-cell therapy. Bone marrow MRD negativity was associated with prolonged survival and those who were MRD positive at 1 month were highly unlikely to convert to MRD negative. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

More from Radhika Bansal

2:22
Outpatient management of CAR-T therapy in multiple myeloma and lymphoma
Radhika Bansal • 9 Dec 2023
1:49
Outpatient management of patients with multiple myeloma treated with bispecific antibodies
Radhika Bansal • 9 Dec 2023
2:00
Prognostic tool to identify CAR-T outcomes in patients with aggressive lymphoma
Radhika Bansal • 11 Dec 2022
2:23
Prophylactic dexamethasone use with CAR-T therapy: real-world practice and outcomes
Radhika Bansal • 11 Dec 2022

Related Videos

4:24
Investigating production failure and out-of-specification production of CAR T-cell therapeutics
Nina Worel • 25 Apr 2024
1:14
Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy • 28 Apr 2024
3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals